Drugs / NY-ESO-1 Plasmid DNA Cancer Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00199849 | Sep 2004 → Sep 2006 | esophageal cancer, non-small cell lung carcinoma, prostate cancer, sarcoma +1 | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 Plasmid DNA Cancer Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00199849 ↗ |
| Known as | pPJV7611 | “NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.” NCT00199849 ↗ |
| Modality | Vaccine | “NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine was administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.” NCT00199849 ↗ |
| Route | Other | “NY-ESO-1 Plasmid DNA Cancer Vaccine administered by particle-mediated epidermal delivery (PMED) at a pressure of 500 psi using the XR-1 Powderject® delivery device.” NCT00199849 ↗ |